Stifel Nicolaus set a $74.00 target price on Kite Pharma Inc. (NASDAQ:KITE) in a report released on Thursday morning. The firm currently has a a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on the company. Vetr raised Kite Pharma from a buy rating to a strong-buy rating and set a $53.26 price target for the company in a research note on Wednesday, July 20th. Jefferies Group reissued a buy rating and set a $72.00 price target on shares of Kite Pharma in a research note on Monday, September 19th. FBR & Co reissued an outperform rating and set a $75.00 price target on shares of Kite Pharma in a research note on Sunday, July 10th. Mizuho reissued a hold rating and set a $80.00 price target on shares of Kite Pharma in a research note on Friday, July 8th. Finally, Barclays PLC increased their price target on Kite Pharma from $60.00 to $65.00 and gave the company an equal weight rating in a research note on Tuesday, September 27th. Three analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of Buy and an average target price of $74.46.

Shares of Kite Pharma (NASDAQ:KITE) traded up 0.11% during midday trading on Thursday, hitting $55.72. The stock had a trading volume of 940,563 shares. The company’s market cap is $2.76 billion. The company’s 50 day moving average is $57.42 and its 200 day moving average is $52.05. Kite Pharma has a 52-week low of $38.41 and a 52-week high of $89.84.

Kite Pharma (NASDAQ:KITE) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.21) by $0.30. The firm earned $4.80 million during the quarter, compared to analyst estimates of $4.86 million. Kite Pharma had a negative return on equity of 32.91% and a negative net margin of 873.86%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.26) earnings per share. On average, analysts anticipate that Kite Pharma will post ($5.87) earnings per share for the current year.

In other Kite Pharma news, SVP Jeffrey Wiezorek sold 1,500 shares of the firm’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $56.90, for a total transaction of $85,350.00. Following the transaction, the senior vice president now directly owns 16,367 shares in the company, valued at approximately $931,282.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Cynthia M. Butitta sold 10,000 shares of the firm’s stock in a transaction on Monday, July 25th. The stock was sold at an average price of $50.94, for a total value of $509,400.00. Following the transaction, the chief operating officer now owns 105,401 shares in the company, valued at $5,369,126.94. The disclosure for this sale can be found here. Company insiders own 20.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. TIAA CREF Investment Management LLC increased its position in Kite Pharma by 0.6% in the first quarter. TIAA CREF Investment Management LLC now owns 158,118 shares of the biopharmaceutical company’s stock valued at $7,259,000 after buying an additional 865 shares during the last quarter. Teachers Advisors Inc. increased its position in Kite Pharma by 7.4% in the first quarter. Teachers Advisors Inc. now owns 86,351 shares of the biopharmaceutical company’s stock valued at $3,964,000 after buying an additional 5,946 shares during the last quarter. Franklin Resources Inc. increased its position in Kite Pharma by 0.7% in the first quarter. Franklin Resources Inc. now owns 402,444 shares of the biopharmaceutical company’s stock valued at $18,476,000 after buying an additional 2,700 shares during the last quarter. BlackRock Group LTD increased its position in Kite Pharma by 52.8% in the first quarter. BlackRock Group LTD now owns 29,816 shares of the biopharmaceutical company’s stock valued at $1,370,000 after buying an additional 10,303 shares during the last quarter. Finally, BlackRock Fund Advisors increased its position in Kite Pharma by 14.6% in the first quarter. BlackRock Fund Advisors now owns 1,508,215 shares of the biopharmaceutical company’s stock valued at $69,242,000 after buying an additional 192,512 shares during the last quarter. Institutional investors own 75.28% of the company’s stock.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy.

5 Day Chart for NASDAQ:KITE

Receive News & Stock Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related stocks with our FREE daily email newsletter.